Cabinet Approves Foreign Business Act Reform in Principle, Opening a Multi-Year Liberalization Track

On April 22, 2025, Thailand's Cabinet approved in principle the first round of amendments to the Foreign Business Act B.E. 2542, the statute that has governed foreign ownership restrictions in Thailand since 1999. This is the origin point of a reform process that, over the following year, produced two further concrete milestones: the Department of Business Development's January 29, 2026 public seminar naming ten candidate businesses for delisting from the Act's restricted categories, and the Cabinet's May 12, 2026 approval in principle of the actual draft Ministerial Regulation and Royal Decree delisting nine of those categories. Both of those later steps are covered in their own separate articles on this site. This article covers where the story begins, what the April 2025 approval actually did and did not do, and what a foreign investor with a biotechnology-adjacent regulated business should be watching for as the reform continues.

What "Approved in Principle" Actually Means

Cabinet approval in principle is a policy green light, not a legal change. It authorizes the responsible ministry, in this case the Ministry of Commerce, to proceed with drafting the specific legal instruments that would implement the policy, and it signals the government's intent and priority, but it does not itself amend the Foreign Business Act or delist any restricted business category. A foreign investor reading news of this approval in April 2025 could not yet rely on any expanded ownership right; what had changed was that the government had committed, at the Cabinet level, to pursuing this reform and had set its initial direction and scope. The gap between this kind of in-principle approval and an actual enacted change can run to a year or more, which is exactly what played out here: the concrete draft delisting instruments did not reach Cabinet approval until May 12, 2026, more than a year later.

The Stated Philosophy Shift

What makes this approval more than a routine policy announcement is the framing behind it. The reform's stated intent is to shift the Foreign Business Act's underlying purpose away from protecting local industries from foreign competition, the framing that has justified the Act's restrictions since 1999, toward building Thailand's long-term economic competitiveness by attracting the foreign capital, technology, and expertise it judges will strengthen the country's position rather than threaten domestic operators. Practically, this means targeting non-strategic industries, sectors where continued restriction no longer serves a clear protective purpose, for eventual delisting, while also streamlining the Department of Business Development's licensing process for whatever restrictions remain. The Ministry of Commerce's intent, as of this approval, was a staged rollout through 2026 rather than a single blanket change, prioritizing four sectors by name: digital services, electric vehicles, semiconductors, and biotechnology.

Biotechnology's Place on the List

Of these four named priority sectors, biotechnology is the one closest to DeeMED's own client base, and it is worth flagging explicitly rather than treating it as background detail. Digital services, EVs, and semiconductors are the sectors that have, so far, actually produced concrete movement: they are the categories that featured most prominently in the ten candidates named at the DBD's January 29, 2026 seminar and in the nine categories the Cabinet approved for delisting on May 12, 2026. Biotechnology's inclusion in the original April 2025 priority list has not yet translated into a named category in either of those two later, more concrete rounds. That does not mean biotechnology has been dropped from consideration, only that it has not yet reached the same stage of the process the other three sectors have.

Why Digital Services, EVs, and Semiconductors Moved First

It is worth understanding why three of the four named priority sectors advanced to concrete delisting candidates within roughly nine months while the fourth, biotechnology, has not. Digital services, electric vehicles, and semiconductors share a common trait: each is a sector where Thailand is competing directly and visibly against other Southeast Asian jurisdictions, Vietnam, Malaysia, and Indonesia among them, for the same pool of mobile foreign investment, and each has an immediate, quantifiable link between foreign ownership liberalization and near-term factory openings, hiring, and export volume. That combination creates political urgency: a government can point to a specific EV plant or semiconductor packaging facility as the direct result of a policy change. Biotechnology, by contrast, tends to involve longer development and regulatory-approval timelines before an ownership change translates into a visible facility or product, and Thailand's biotechnology sector is less obviously in a head-to-head race against a specific regional competitor the way EV assembly or semiconductor packaging is. None of this means biotechnology is being deprioritized as a matter of policy; it means the sectors with the fastest visible payoff moved through the pipeline first, which is a common and unsurprising pattern in staged regulatory reform generally, not a sign this particular sector has been shelved.

The Forward Timeline

The reform proceeded in three distinct steps over roughly thirteen months. First, the April 22, 2025 Cabinet approval in principle set the policy direction and named the four priority sectors. Second, the DBD held a public seminar on January 29, 2026 naming ten specific candidate businesses under consideration for delisting from the Act's restricted categories, the first point at which the reform moved from a general sector priority list to named, specific businesses. Third, the Cabinet approved in principle the actual draft Ministerial Regulation and Royal Decree on May 12, 2026, delisting nine of those ten candidates, the first point at which the reform produced an actual drafted legal instrument rather than a policy statement or a seminar presentation. Each step narrowed the gap between stated intent and enacted law, but as of the most recent milestone, biotechnology had not yet appeared as one of the nine delisted categories.

What a Biotechnology-Adjacent Investor Should Watch For

A foreign investor operating or planning a biotechnology-adjacent regulated entity in Thailand, whether that overlaps with pharmaceutical manufacturing, medical device production, or another Thai FDA or DTAM-regulated activity, should treat biotechnology's presence on the original 2025 priority list as a genuine signal of government intent, not as a promise of imminent ownership liberalization. The concrete delisting work completed so far has moved fastest in digital services, EVs, and semiconductors, sectors with more immediate political and economic urgency attached to them; biotechnology's turn may come in a later round of this same staged process, or it may end up handled through a separate mechanism entirely, such as expanded BOI promotion rather than an outright FBA delisting. The prudent approach for now is to keep structuring any biotechnology-adjacent Thai entity under the ownership rules that actually apply today, whether that means a Foreign Business License, BOI promotion, or a properly structured joint venture, while monitoring each subsequent DBD seminar and Cabinet announcement for whether biotechnology finally appears in a named delisting round.

Structuring a compliant Thai entity today, without waiting on a reform that has not yet reached biotechnology, is exactly the kind of planning DeeMED works through with clients forming a Thai company to hold a Thai FDA, DTAM cannabis, or hazardous-substance license in a regulated, biotechnology-adjacent sector.